Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AL8326 / Advenchen
NCT06247605: A Phase IIII Study of AL8326 in Small Cell Lung Cancer	Recruiting	3	243	RoW	AL8326 tablets, AL8326, placebo	Advenchen Laboratories Nanjing Ltd.	Small Cell Lung Carcinoma	07/28	07/29
NCT05363280: Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC	Recruiting	2	36	US	AL8326 low dose group, AL8326 middle dose group, AL8326 high dose group	Advenchen Pharmaceuticals, LLC.	Small Cell Lung Cancer	12/24	12/25
NCT04890795: A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer	Recruiting	1/2	237	RoW	AL8326 tablets, AL8326	Advenchen Laboratories Nanjing Ltd.	Small Cell Lung Cancer	09/21	09/21
NCT06794957: A Study of AL8326 in Non-Small Cell Lung Cancer	Active, not recruiting	1	158	RoW	AL8326 tablets, AL8326	Advenchen Laboratories, LLC	Non-small Cell Lung Cancer	12/27	12/27
NCT05486598: A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects	Recruiting	1	16	RoW	AL8326 tablets, AL8326	Advenchen Laboratories Nanjing Ltd.	Diet, High-Fat, Pharmacokinetics	12/22	12/22
NCT04890587: A Phase I Study of AL8326 in Advanced Solid Tumor	Recruiting	1	40	RoW	AL8326 tablets, AL8326	Advenchen Laboratories Nanjing Ltd.	Advanced Solid Tumors	12/23	12/23